Free Trial
→ NYSE biotech company's drug could be as revolutionary as penicillin! (From Financial Markets Daily) (Ad) Free LEN Stock Alerts

Lennar (LEN) Stock Forecast & Price Target

$142.49
-0.14 (-0.10%)
(As of 11:04 AM ET)
Compare
Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends

Lennar - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold
Based on 17 Analyst Ratings

Consensus Price Target

$166.69
16.98% Upside
High Forecast$237.00
Average Forecast$166.69
Low Forecast$117.00
TypeCurrent Forecast
7/9/23 to 7/8/24		1 Month Ago
6/9/23 to 6/8/24		3 Months Ago
4/10/23 to 4/9/24		1 Year Ago
7/9/22 to 7/9/23
Consensus Rating
Hold
Hold
Hold
Hold
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
9 Buy rating(s)
11 Buy rating(s)
11 Buy rating(s)
8 Buy rating(s)
Hold
5 Hold rating(s)
3 Hold rating(s)
3 Hold rating(s)
6 Hold rating(s)
Sell
3 Sell rating(s)
3 Sell rating(s)
3 Sell rating(s)
2 Sell rating(s)
Consensus Price Target$166.69$163.88$163.88$123.20
Forecasted Upside16.98% Upside8.67% Upside8.13% Upside17.79% Upside

LEN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

LEN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Lennar Stock vs. The Competition

TypeLennarConstruction CompaniesS&P 500
Consensus Rating Score
2.35
2.57
2.50
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside16.87% Upside72.88% Upside12.25% Upside
News Sentiment RatingNeutral News
Positive News
Positive News
Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
7/2/2024Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating		B. Horne
Subscribe to MarketBeat All Access for the recommendation accuracy rating		DowngradeOutperform ➝ Market Perform
7/2/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating		A. Pettinari
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated RatingBuy ➝ Neutral$174.00 ➝ $164.00+12.38%
6/27/2024Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating		C. Graja
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost TargetBuy ➝ Buy$175.00 ➝ $180.00+20.90%
6/20/2024JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingMarket Outperform ➝ Market Outperform$170.00 ➝ $170.00+14.49%
6/20/2024BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetBuy ➝ Buy$177.00 ➝ $175.00+17.86%
6/20/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingUnderperform ➝ Underperform$145.00 ➝ $145.00-3.11%
NYSE biotech company's drug could be as revolutionary as penicillin! (Ad)

NV-387 could be a single drug to treat all of the "tripledemic" viruses and more! See how NV-387 could be highly valuable for preparedness against novel viral epidemics and pandemics all while building shareholder value for this growing biotech company

Click here for the company ticker
6/20/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetNeutral ➝ Neutral$157.00 ➝ $154.00+3.55%
6/20/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetOutperform ➝ Outperform$238.00 ➝ $237.00+59.36%
6/18/2024Keefe, Bruyette & Woods
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingOutperform ➝ Outperform$183.00 ➝ $183.00+23.07%
6/18/2024Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating		J. Mccanless
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated RatingUnderperform ➝ Underperform$144.00 ➝ $144.00-8.00%
3/15/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetOverweight ➝ Overweight$173.00 ➝ $180.00+14.86%
3/15/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetOverweight ➝ Overweight$165.00 ➝ $175.00+11.67%
3/15/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingMarket Perform ➝ Market Perform
3/15/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetBuy ➝ Buy$190.00 ➝ $198.00+26.35%
3/14/2024Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetSell ➝ Sell$110.00 ➝ $122.00-23.23%
12/18/2023The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetBuy ➝ Buy$138.00 ➝ $158.00+5.34%
11/27/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageHold$117.00-8.33%
6/14/2023Seaport Res Ptn
Subscribe to MarketBeat All Access for the recommendation accuracy rating		K. Zener
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated RatingBuy
6/14/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost Target$103.00 ➝ $120.00+3.44%
3/16/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetNeutral$88.00 ➝ $96.00-4.18%
12/16/2022KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetOverweight$100.00 ➝ $110.00+16.66%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 11:22 AM ET.

LEN Forecast - Frequently Asked Questions

What is Lennar's forecast for 2024?

According to the research reports of 17 Wall Street equities research analysts, the average twelve-month stock price forecast for Lennar is $166.69, with a high forecast of $237.00 and a low forecast of $117.00.

Should I buy or sell Lennar stock right now?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lennar in the last twelve months. There are currently 3 sell ratings, 5 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" LEN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in LEN, but not buy additional shares or sell existing shares.

Does Lennar's stock price have much upside?

According to analysts, Lennar's stock has a predicted upside of 11.15% based on their 12-month stock forecasts.

Has Lennar been downgraded by Wall Street analysts recently?

Over the previous 90 days, Lennar's stock had 1 downgrade by analysts.

What analysts cover Lennar?

Lennar has been rated by research analysts at Argus, BTIG Research, Citigroup, Evercore ISI, JMP Securities, JPMorgan Chase & Co., Keefe, Bruyette & Woods, Raymond James, Royal Bank of Canada, and Wedbush in the past 90 days.

Do Wall Street analysts like Lennar more than its competitors?

Analysts like Lennar less than other "construction" companies. The consensus rating for Lennar is Hold while the average consensus rating for "construction" companies is Moderate Buy. Learn more on how LEN compares to other companies.


Related Companies:
Today's Ratings:
Top Rated Stocks:
More Ratings Tools:
This page (NYSE:LEN) was last updated on 7/8/2024 by MarketBeat.com Staff

From Our Partners
Biden to Launch “FedNOW” [Move Your Money Now]
Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...
Priority Gold | Sponsored
Write this ticker symbol down…
A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...
StocksToTrade | Sponsored
NYSE biotech company's drug could be as revolutionary as penicillin!
NV-387 could be a single drug to treat all of the "tripledemic" viruses and more! See how NV-387 could be h...
Financial Markets Daily | Sponsored
50-year Wall Street Legend: “Prepare for a cash avalanche”
The Dow crossed 40,000 for the first time in history… The S&P has hit over 30 all-time highs since the star...
Chaikin Analytics | Sponsored
Obama wins Presidential debate
When I said Obama would seek a third term… They called me a conspiracy theorist, they said it couldn’t happ...
Porter & Company | Sponsored
Trump’s Gift Could Unleash $51 Billion in New Wealth
In January 2021, Donald Trump silently rolled out a special gift to the American public… One that top house...
Wealthpin Pro | Sponsored
New Government Policy to Wipe Out Seniors Wealth
Don't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of o...
Oasis Gold | Sponsored
Biden Nomination CANCELED?
And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...
The Freeport Society | Sponsored